Intravenous bisphosphonate prevents symptomatic osteoporotic vertebral collapse in patients after liver transplantation
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Osteoporosis is common in patients with chronic cholestatic liver disease, and atraumatic spinal fracture is a recognized complication after orthotopic liver transplantation. Bisphosphonates are potent inhibitors of osteoclast bone resorption and have been successfully used to treat postmenopausal osteoporosis. We examined whether preoperative bone mineral density can predict the risk of fracture after orthotopic liver transplantation and whether intravenous bisphosphonate can prevent fractures in high-risk patients. Beginning in February 1993, standard bone mineral density measurements of the lumbar spine were performed as part of routine pretransplantation assessment. On the basis of a preliminary analysis from January 1995, patients with a lumbar spine bone mineral density of <0.84 g/cm2, or <84% of the predicted value (age/sex), were treated with intravenous bisphosphonate (pamidronate disodium) every 3 months before and for 9 months after liver transplantation. Bone mineral density measurements were available in 90 of 136 consecutive first transplants performed in our unit from February 1993 to September 1996. Before the use of pamidronate, 7 patients sustained symptomatic vertebral fractures. Their mean spine bone mineral density was lower than in the 38 patients with no clinical evidence of fracture (81.8% +/- 12.3% v 94.2% +/- 10.2%; P = .006). Since the introduction of pamidronate, no symptomatic vertebral fractures have occurred. Of 29 surviving patients with bone mineral density <0.84 g/cm2 before transplantation, 38% who did not receive treatment with pamidronate suffered spontaneous fracture, whereas 0 of 13 who received treatment suffered such a complication. A low lumbar spine bone mineral density is associated with a high risk of symptomatic vertebral fracture after liver transplantation. These results suggest that this risk is considerably reduced by the administration of intravenous bisphosphonate before and after transplantation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Eastell, R., Dickson, R. E., Hodgson, S. F., Wiesner, R. H., Porayko, M. K., Wahner, H. W., Cedel, S. L., Riggs, L. B., & Krom, R. A. F. (1991) · Hepatology · doi:10.1002/hep.1840140215 · Cited by 297
CALCITONIN FOR PREVENTION OF POSTMENOPAUSAL BONE LOSS
Macintyre, I., Whitehead, M. I., Banks, L. M., Stevenson, J. C., Wimalawansa, S. J., & Healy, M. J. R. (1988) · The Lancet · doi:10.1016/s0140-6736(88)91712-6 · Cited by 204
Cited by
Impracticability of Informed Consent in the Registry of the Canadian Stroke Network
Tu, J. V., Willison, D. J., Silver, F. L., Fang, J., Richards, J. A., Laupacis, A., & Kapral, M. K. (2004) · New England Journal of Medicine · doi:10.1056/nejmsa031697 · Cited by 422
Osteoporosis Due to Cancer Treatment: Pathogenesis and Management
Pfeilschifter, J., & Diel, I. J. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.7.1570 · Cited by 363
Bone disorders in chronic liver disease
Collier, J. (2007) · Hepatology · doi:10.1002/hep.21852 · Cited by 238
Zein, C. O., Jorgensen, R. A., Clarke, B., Wenger, D. E., Keach, J. C., Angulo, P., & Lindor, K. D. (2005) · Hepatology · doi:10.1002/hep.20866 · Cited by 142
Rouillard, S., & Lane, N. E. (2001) · Hepatology · doi:10.1053/jhep.2001.20533 · Cited by 125
Osteoporosis in liver diseases and after liver transplantation
Hay, J. E. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)00143-0 · Cited by 72
“4%) in the alendronate group; no significant side effects were seen with either therapy ([121], #307).”
BackgroundDiagnosis and Management of Cirrhosis-Related Osteoporosis
Santos, L. A. A., & Romeiro, F. G. (2016) · BioMed Research International · doi:10.1155/2016/1423462 · Cited by 66
Prophylactic bisphosphonate treatment prevents bone fractures after liver transplantation
Bodingbauer, M., Wekerle, T., Pakrah, B., Roschger, P., Peck-Radosavljevic, M., Silberhumer, G., Grampp, S., Rockenschaub, S., Berlakovich, G., Steininger, R., et al. (2007) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2007.01844.x · Cited by 54
“Many of these studies have been small and most have not been randomized or controlled (7).”
BackgroundTreatment of bone disorders in liver disease
Parés, A., & Guañabens, N. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2006.06.007 · Cited by 50
“The efficacy of pamidronate, a parenterally administered bisphosphonate with a marked antiresorptive capacity, has been evaluated in patients with end-stage chronic liver disease, prior to and after liver transplantation [49,87,88].”
BackgroundBone disorders in patients with chronic liver disease awaiting liver transplantation
Loria, I., Albanese, C., Giusto, M., Galtieri, P. A., Giannelli, V., Lucidi, C., Di Menna, S., Pirazzi, C., Corradini, S. G., Mennini, G., et al. (2010) · Transplantation Proceedings · doi:10.1016/j.transproceed.2010.03.096 · Cited by 48
Atamaz, F., Hepguler, S., Akyildiz, M., Karasu, Z., & Kilic, M. (2006) · Osteoporosis International · doi:10.1007/s00198-006-0082-5 · Cited by 46
Metadata
- Authors
- Reeves, H. L., Francis, R. M., Manas, D. M., Hudson, M., & Day, C. P.
- Venue
- Liver Transplantation and Surgery
- Publisher
- Wiley
- Published
- 1998-09
- Volume
- 4
- Issue
- 5
- Pages
- 404-409
- ISSN
- 1074-3022 (ISSN-L)
- OpenAlex
- W2001525486
- Cited by
- 108
- References
- 3
- FWCI
- 8.02
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.